Top 20 Pharma Exceeds Recruitment Targets and Reduces Screen Failures Across 188 Sites
A top-20 pharmaceutical company was conducting a Phase III breast cancer study in 16 countries across North America, Europe, and
Consideration
Top 20 pharma accelerates training and enrollment across 650 Site Staff
A top-20 pharmaceutical company was planning a large Phase III trial of a new vaccine for a mosquitoborne viral disease.
Open Demo | Advarra Study Collaboration
LIVE DEMO | AUG 21, 2025 Introducing Site-Facing SSU Milestone Tracking Advarra’s Study Collaboration solution’s newest release redefines how clinical
Advarra Study Collaboration
Our approach We deliver the insights and efficiency that study design, site identification and feasibility, activation, and enrollment tracking demand.
Advarra Enroll Info Sheet
Set up sites for recruitment success with the only site-sponsor collaboration solution integrated into the site’s study startup workflow.
Advarra Enroll
Improve enrollment and patient engagement Planning and screening Enable sites with a dedicated site-specific recruitment plan and functionality to quickly
Advarra Study Startup Info Sheet
Guide sites and study teams with the only site-sponsor collaboration solution that provides immediate visibility, helping you hit every milestone on time.
CCPay
CCPay enables clinical trial sites to streamline participant payment workflows, track payments in real time, and enhance overall financial management.
Advarra Study Startup
First-of-its-kind site-facing startup milestone tracker With Study Collaboration’s newly expanded milestone functionality, sites have a clear, real-time view of their
Solutions For Study Startup
Our approach We deliver the insights and efficiency that study design, site identification and feasibility,activation, and enrollment tracking demand. Intelligent
Clinical Research Staffing
Reduce the burden of testing and documentation with precompiled validation materials, available through an annual subscription.
Central Oncology Review
Advarra meets the growing needs of oncology by offering robust human subject protections that cancer research institutions expect.